Results 191 to 200 of about 2,243,647 (283)

Metabolic Reprogramming of Cancer Stem Cells: Targeting Lipid Flux and Mitochondrial Plasticity to Overcome Therapeutic Resistance

open access: yesCancer Medicine, Volume 15, Issue 9, September 2026.
Metabolic reprogramming in cancer stem cells: lipid flux, mitochondrial plasticity, and therapeutic resistance. Lipid metabolism in CSCs: de novo lipogenesis, CD36 uptake, FAO, lipid droplets, and membrane remodeling. Mitochondrial dynamics in CSC survival: fusion, fission, mitophagy, OXPHOS switching, and ROS regulation.
Daniel Ejim Uti   +5 more
wiley   +1 more source

Recent Advances in Microwave and Ultrasound Assisted Synthesis of Quinoline Derivatives as Anticancer Agents

open access: yesChemistry &Biodiversity, Volume 23, Issue 9, September 2026.
Green microwave‐ and ultrasound‐assisted synthesis enables the rapid, sustainable preparation of quinoline‐based anticancer agents with improved reaction efficiency, higher yields, and enhanced biological activity. ABSTRACT Quinoline derivatives represent a privileged class of heterocyclic compounds with remarkable structural diversity and broad ...
Rohit Pal   +5 more
wiley   +1 more source

Clinical Benefit of Pembrolizumab in Lynch Syndrome‐Associated Advanced Ovarian Cancer With Germline MSH6 Variant: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT This case highlights the importance of genetic evaluation during treatment in young patients with advanced ovarian cancer. Lynch syndrome caused by a germline MSH6 pathogenic variant was diagnosed during first‐line maintenance therapy, and pembrolizumab achieved a durable response in recurrent disease.
Tomomi Yokozawa   +7 more
wiley   +1 more source

USP43 promotes gemcitabine resistance by regulating cholesterol homeostasis through E2F1 stabilization in bladder cancer. [PDF]

open access: yesJ Exp Clin Cancer Res
Li M   +14 more
europepmc   +1 more source

AZD6738 (Ceralasertib) Enhances Trifluridine's Antitumor Effect in 5‐FU–Resistant Colorectal Cancer Cells

open access: yesCancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Resistance to 5‐fluorouracil (5‐FU) remains a major obstacle in colorectal cancer (CRC) treatment. Trifluridine (FTD), the active component of TAS‐102, exerts cytotoxicity through DNA incorporation and reportedly remains active in 5‐FU‐resistant tumors, though with limited clinical efficacy.
Shuhei Uehara   +11 more
wiley   +1 more source

Comprehensive Profiling of ac4C RNA Modification Identifies CERCAM in Cancer‐Associated Fibroblasts as a Key Prognostic and Microenvironmental Regulator in Colorectal Cancer

open access: yesCancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background N4‐acetylcytidine (ac4C) RNA modification has emerged as a critical epigenetic regulator in tumorigenesis and progression. However, the comprehensive landscape of ac4C modification in colorectal cancer (CRC), particularly its orchestration of the tumor microenvironment (TME) and stromal crosstalk, remains largely unexplored.
Yang Xia   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy